<DOC>
	<DOCNO>NCT01443065</DOCNO>
	<brief_summary>This multicentre , open-label , randomized phase II trial ongoing 30 centre France . Main eligibility criterion include : histologically proven adenocarcinoma stomach , esophagus gastroesophageal junction ; locally advance metastatic disease ; measurable disease ( RECIST 1.1 ) ; know HER2 overexpression ; prior palliative chemotherapy .</brief_summary>
	<brief_title>MEGA ( Met EGFR Inhibition Gastroesophageal Adenocarcinoma ) : FOLFOX Alone Combination With AMG 102 Panitumumab First-line Treatment Patients With Advanced Gastroesophageal Adenocarcinoma</brief_title>
	<detailed_description>Patients randomise modify FOLFOX6 ( oxaliplatin 85 mg/m2 , FA 400 mg/m² , FU 400 mg/m² bolus 2400 mg/m² 46 hr ) alone combine either panitumumab ( 6 mg/kg ) AMG 102 ( 10 mg/kg ) , every two week unacceptable toxicity disease progression . Judgment criterion include 4-month progression-free survival ( PFS ) rate ( primary endpoint ) , OS , objective response rate , safety . Ancillary study aim identify candidate predictive prognostic biomarkers among functional molecular alteration EGFR/RAS/RAF HGF/c-Met pathway , monitor circulate tumour cell circulate immune cell ( myeloid derive suppressor cell , NK cell ) sequential blood sample take baseline study treatment . A total 165 pt enrol ( Fleming 's one-step design )</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven adenocarcinoma stomach , esophagus cardia ( without signet ring cell ; intestinal , diffuse mixed form ) . Locally advanced ( non resectable ) metastatic disease . Measurable disease ( least one measurable tumor ) accord RECIST V1.1 criterion ( tumor locate previous field radiation ) . Absence previous palliative chemotherapy . Previous neoadjuvant adjuvant chemotherapy ( alone combinated radiotherapy ) authorize , include biotherapy ( except antiEGFR anticMet / HGF ) , stop least 12 month inclusion . Previous radiotherapy authorize stop least 14 day randomization least one measurable target outside radiation area present . No major surgery ≤ 28 day , minor surgery ≤ 14 day , prior randomization Sites disease evaluate within 28 day prior randomization thoracicabdominalpelvic CT scan ( abdominalpelvic MRI plus Chest Xray ) . Age ≥ 18 year . Patient general status : ECOG 01 . Life expectancy ≥ 3 month . Hemoglobin &gt; = 9 g/L ( transfusion authorize necessary ) , PNN ≥ 1,5.109/l , platelet ≥ 100.109/l . Hepatic transaminase ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 ULN case hepatic metastasis ) , alkaline phosphatase ≤ 2.5 ULN ( ≤ 5 ULN case hepatic metastasis ) , total bilirubinemia ≤ 1.5 ULN ) Creatinine clearance ( calculate measure ) ≥ 50 ml / min , serum creatinine &gt; 1.5 ULN Prothrombin time ( PT ) ≥ 60 % , INR &lt; 1,5 ( except anticoagulant therapy ) Magnesemia calcemia ≥ Lower Limit Normal ( LLN ) Negative Pregnancy test woman childbearing age . Information give patient sign informed consent . Public Health insurance coverage . Sample tumour ( primitive metastatic ) available . Known brain leptomeningeal metastasis . Positive HER2 Status ( IHC 3+ IHC2+/FISH CISH+ ) . contraindication , allergy hypersensitivity ANY OF study treatment . Prior Treatment EGFR inhibitor HGF / cMet inhibitor . Patient already include another clinical trial test experimental drug . Peripheral edema &gt; grade 2 . Proteinuria &gt; 1 g/24h Clinically significant cardiovascular disease ( unstable angina pectoris , severe congestive heart failure , uncontrolled severe cardiac arrhythmia ) within 12 month prior randomization . Thrombosis ischemic vascular event last 12 month ( deep venous thrombosis , pulmonary embolism , STROKE establish cerebral infarction , myocardial infarction ) . Medical history sign interstitial pneumopathy pulmonary fibrosis . Peripheral neuropathy &gt; grade 1 . Clinically significant hemorrhage upper gastrointestinal tract ( require blood transfusion hemostatic interventional procedure . Actively evolutive inflammatory bowel disease intestinal disease cause chronic diarrhea ( ≥ grade 2 ) . Any uncontrolled concomitant disease ( e.g. , uncontrolled diabetes ) medical history ( e.g. , organ transplantation ) , accord opinion investigator , may interfere interpretation study result . Any comorbidity situation , accord opinion investigator , could increase risk toxicity ( e.g. , Dihydropyrimidine dehydrogenase deficiency ) . Chronic active HIV , HBV HCV infection . Severe and\or heal wound . Any active infection require systemic treatment , uncontrolled infection within 14 day randomization . Other concomitant malignancy history cancer ( except carcinoma situ cervix , non melanoma skin cancer , curative intent treatment ) , except consider complete remission least 5 year randomization . Pregnant woman woman might become pregnant study ( plan become pregnant within 6 month last administration study drug ) lactate woman . Men woman age procreation abide use highly efficient contraceptive mean ( accord current institutional standard ) , alternatively , use abstinence study treatment 6 month last administration study drug . Patient unwilling comply medical followup require trial geographic social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Locally advanced ( non operable ) metastatic</keyword>
	<keyword>First line treatment</keyword>
</DOC>